COVID-19 vaccine developer Pfizer said it will likely know whether its vaccine is effective by the end of October, according to MarketWatch.
- The announcement came Friday. Pfizer’s premarket trading rose after the announcement.
- The company said it plans to apply for emergency use authorization by the second half of November, too.
- The FDA needs two months of data before it can approve a vaccine for emergency use.
What they’re saying:
- “Based on current trail enrollment and dosing pace, we estimate we will reach this milestone in the third week of November,” Chief Executive Albert Bourla wrote in an open letter.
- “So let me be clear, assuming positive data, Pfizer will apply for emergency authorization use in the U.S. soon after the safety milestone is achieved in the third week of November,” Bourla wrote. “All the data contained in our U.S. application would be reviewed not only by the FDA’s own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency.”
Is this true?
View Comments
Dr. Scott Gottlieb recently told CNBC there will likely be top-line results by November. The vaccine itself wouldn’t ready for a few months after, though.
- “I think it’s very unlikely. I think it’s more likely you’re going to get a top-line result some point in November and maybe be able to make a decision about an emergency use authorization after that.”